Replies to post #539061 on NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

At the risk of being too repetitive,

1. LP, MB, AB, LG, and directors, have much more common shares and equivalents than any of us individually, with more to come in bonuses

2. Their real reward for all the years of their efforts is directly proportional to the value of their holdings

3. We common shareholders benefit if the insiders benefit in proportion as well

4. LP literally is expert in bringing biotech to commercialization, IP, finances and M&A, agreements, and is known and connected in government and NIH circles

I never bet on the ponies, however I like the looks of this horse investment, especially now. Putting the horse before the cart, so to speak :-)

All imo not investment advice you do you!

[lrdpdx77]

Also, the increase in authorized shares primarily covers the warrants and options that would be included in any calculation of fully diluted shares. The stock price and any valuation of the company should reflect the fully diluted shares, so it is theoretically possible that the newly authorized shares shouldn't cause much dilution as they should already be factored into valuations. I believe the proposal may in fact be viewed as a positive as it covers a real need (reduces the risk that the company doesn't have enough authorized shares to cover the potential exercise of the options, warrants and potential conversion of preferred shares) and may provide significant funds to the company upon the exercise of the options and warrants. Also having sufficient authorized shares may make the Preferred C shares more attractive to purchasers.